CL2017003095A1 - Carbonato de calcio amorfo estabilizado con polifosfatos o bisfosfonatos - Google Patents

Carbonato de calcio amorfo estabilizado con polifosfatos o bisfosfonatos

Info

Publication number
CL2017003095A1
CL2017003095A1 CL2017003095A CL2017003095A CL2017003095A1 CL 2017003095 A1 CL2017003095 A1 CL 2017003095A1 CL 2017003095 A CL2017003095 A CL 2017003095A CL 2017003095 A CL2017003095 A CL 2017003095A CL 2017003095 A1 CL2017003095 A1 CL 2017003095A1
Authority
CL
Chile
Prior art keywords
calcium carbonate
bisphosphonates
polyphosphates
acc
amorphous calcium
Prior art date
Application number
CL2017003095A
Other languages
English (en)
Inventor
Yosef Ben
Yigal Dov Blum
Hagay Moshe
Ben Ashkenazi
Original Assignee
Amorphical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorphical Ltd filed Critical Amorphical Ltd
Publication of CL2017003095A1 publication Critical patent/CL2017003095A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/24—Phosphorous; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN PROPORCIONA COMPOSICIONES SÓLIDAS DE CARBONATO DE CALCIO AMORFO (ACC) Y UN POLIFOSFATO, BISFOSFONATO O SALES FARMACÉUTICAS DE LOS MISMOS COMO ESTABILIZADOR. DICHOS ESTABILIZADORES ESTABILIZAN EL ACC Y EVITAN LA CRISTALIZACIÓN EN CARBONATO DE CALCIO CRISTALINO (CCC) DURANTE UN LARGO PERÍODO DE TIEMPO, INCLUSO EN SUSPENSIÓN ACUOSA. LA INVENCIÓN PROPORCIONA ADEMÁS UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE LAS COMPOSICIONES SÓLIDAS DE ACC ASÍ COMO SU USO EN EL TRATAMIENTO DE CIERTAS ENFERMEDADES Y AFECCIONES.</p>
CL2017003095A 2015-06-04 2017-12-04 Carbonato de calcio amorfo estabilizado con polifosfatos o bisfosfonatos CL2017003095A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562170712P 2015-06-04 2015-06-04

Publications (1)

Publication Number Publication Date
CL2017003095A1 true CL2017003095A1 (es) 2018-05-11

Family

ID=57440881

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2017003066A CL2017003066A1 (es) 2015-06-04 2017-12-01 Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
CL2017003095A CL2017003095A1 (es) 2015-06-04 2017-12-04 Carbonato de calcio amorfo estabilizado con polifosfatos o bisfosfonatos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2017003066A CL2017003066A1 (es) 2015-06-04 2017-12-01 Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal

Country Status (14)

Country Link
US (4) US10758565B2 (es)
EP (2) EP3302506B1 (es)
JP (3) JP7007716B2 (es)
KR (1) KR102833797B1 (es)
CN (3) CN107921061A (es)
AU (3) AU2016273059B2 (es)
BR (1) BR112017026131B1 (es)
CA (2) CA2988068C (es)
CL (2) CL2017003066A1 (es)
ES (1) ES3056807T3 (es)
HK (2) HK1253702A1 (es)
IL (2) IL256065B2 (es)
RU (2) RU2739563C2 (es)
WO (2) WO2016193982A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3174409A4 (en) * 2014-07-31 2018-01-17 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
ES3052833T3 (en) 2016-01-18 2026-01-15 Amorphical Ltd Stabilized amorphous calcium carbonate as a supplement for cell culture media
US20220152094A1 (en) * 2016-01-18 2022-05-19 Amorphical Ltd. Stabilized amorphous calcium carbonate for treatment of neurological, muscular and infertility diseases or conditions
JP6873389B2 (ja) 2016-01-18 2021-05-19 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム
JP7152785B2 (ja) 2016-10-25 2022-10-13 アモーフィカル リミテッド． 白血病治療のための非晶質炭酸カルシウム
US11007170B2 (en) 2017-02-02 2021-05-18 Panaxia Pharmaceutical Industries Ltd. Composition for buccal or sublingual administration of cannabis extract and methods for making same
CN110183876A (zh) * 2019-06-21 2019-08-30 中国矿业大学(北京) 重质碳酸钙改性剂、重质碳酸钙的改性方法、改性重质碳酸钙及其应用
IL289237B2 (en) * 2019-07-23 2026-03-01 Amorphical Ltd Amorphous calcium carbonate for improving athletic performance
WO2021181372A1 (en) * 2020-03-11 2021-09-16 Amorphical Ltd. Amorphous calcium carbonate for treatment of acidosis
EP4284343A4 (en) * 2021-01-28 2024-12-11 Amorphical Ltd. Particles comprising amorphous divalent metal carbonate
WO2024059842A2 (en) * 2022-09-16 2024-03-21 Augusta University Research Institute, Inc. Compositions and methods of minimizing long covid
WO2025169195A1 (en) * 2024-02-07 2025-08-14 Amorphical Ltd. Methods of increasing sensitivity of bacteria resistant to antibiotics and inhibiting biofilm formation
WO2026014535A1 (ja) * 2024-07-11 2026-01-15 国立大学法人旭川医科大学 子宮内膜症の予防又は治療用組成物
WO2026014534A1 (ja) * 2024-07-11 2026-01-15 国立大学法人旭川医科大学 間質性膀胱炎・膀胱痛症候群の予防又は治療用医薬組成物

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4237147A (en) 1974-01-04 1980-12-02 Monsanto Company Stabilized amorphous calcium carbonate
US4199496A (en) 1974-09-05 1980-04-22 Johnson Edwin L Process for the recovery of chemicals from the shells of crustacea
JPS56124368A (en) * 1980-02-25 1981-09-30 Monsanto Co Stabilized amorphous calcium carbonate
EP0052677B1 (en) 1980-11-21 1985-01-09 Monsanto Company Concentrates for the preparation of carbonated beverages
US4964894A (en) 1986-03-31 1990-10-23 Freepons Donald E Plant growth regulators derived from chitin
DE3875867T2 (de) 1987-08-28 1993-04-01 Norwich Eaton Pharma Kalziumzusaetze.
GB2217988B (en) 1988-04-11 1992-04-01 Gould Leonard W Regimen for increasing bone density in humans
DE3853422T2 (de) 1988-06-09 1995-10-26 Innogenetics Nv HIV-3-Retrovirus und seine Verwendung.
US5886012A (en) 1989-03-22 1999-03-23 Peter K. T. Pang Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers
US5460803A (en) 1989-05-24 1995-10-24 American Dental Association Health Foundation Methods and compositions for mineralizing and fluoridating calcified tissues
US5037639A (en) 1989-05-24 1991-08-06 American Dental Association Health Foundation Methods and compositions for mineralizing calcified tissues
US6348571B1 (en) 1994-09-12 2002-02-19 Northwestern University Corticotropin release inhibiting factor and methods of using same
JPH099871A (ja) 1995-07-03 1997-01-14 Kita Nippon Shokuhin Kk 菓 子
WO1997024069A1 (en) 1995-12-26 1997-07-10 Holomed Aps A method and system for generating an x-ray image
JPH10236957A (ja) 1997-02-24 1998-09-08 Bankaku Souhonpo:Kk 骨粗鬆症の改善剤
US20060165784A1 (en) 1997-05-06 2006-07-27 Zhao Jin R Calcium supplement
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
US20030077604A1 (en) 2000-10-27 2003-04-24 Yongming Sun Compositions and methods relating to breast specific genes and proteins
JP2002205947A (ja) 2000-12-11 2002-07-23 Chafflose Corporation 水虫治療薬
EP1416916B1 (en) 2001-08-16 2007-10-17 Cmp Therapeutics Limited Chitin microparticles and their medical uses
US8603514B2 (en) * 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
JP2003292453A (ja) 2002-04-02 2003-10-15 Asahi Kasei Corp 骨疾患治療用医薬複合剤
JP2004081739A (ja) 2002-08-29 2004-03-18 Mitsuru Akashi ハイドロキシアパタイト−ポリマー複合材料の止血用組成物
WO2005025581A1 (fr) 2003-09-17 2005-03-24 Third Military Medical University, Chinese People's Liberation Army, P.R. Of China Utilisation de la n-acetyl-d-aminoglycosamine pour la preparation de medicaments de traitement du cancer et des metastases
GB0324918D0 (en) 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
KR100561231B1 (ko) 2004-05-18 2006-03-15 한국지질자원연구원 표면개질에 의한 비정질 탄산칼슘 제조방법
CA2567972C (en) 2004-05-26 2015-07-28 Ben-Gurion University Of The Negev Research And Development Authority Orally-administrable compositions comprising stable amorphous calcium carbonate
WO2006043966A2 (en) 2004-10-15 2006-04-27 University Of Tennessee Research Foundation Methods for inducing apoptosis in adipocytes
SG158153A1 (en) 2004-12-21 2010-01-29 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
CN101090949B (zh) 2004-12-22 2013-06-05 索尔维公司 碱土金属碳酸盐的耐酸粒子
DE102005047807A1 (de) * 2005-06-04 2006-12-07 Solvay Infra Bad Hönningen GmbH Modifizierte Nanopartikel
US20070041506A1 (en) 2005-08-22 2007-02-22 Michelle Bottino Digital sensor holder
GB0522045D0 (en) 2005-10-28 2005-12-07 Novartis Ag Pharmaceutical compositions
AU2007207429A1 (en) 2006-01-19 2007-07-26 Warsaw Orthopedic, Inc. Injectable and moldable bone substitute materials
IL178495A (en) * 2006-10-05 2014-12-31 Univ Ben Gurion Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions
US20080226715A1 (en) * 2007-03-16 2008-09-18 Albert Cha Therapeutic compositions and methods
PL2211873T3 (pl) 2007-10-22 2013-01-31 Amorphical Ltd Stabilny amorficzny węglan wapnia wchodzący w skład fosforylowanych aminokwasów
WO2009087553A1 (en) 2008-01-02 2009-07-16 Aurobindo Pharma Limited Kits for administering bisphosphonates
CN101314031A (zh) 2008-07-14 2008-12-03 王冰 一种改善骨营养的制剂
ES2332636B1 (es) 2008-08-06 2011-02-10 Universitat De Les Illes Balears Composicion de liquido de dialisis.
EP2334292B1 (en) 2008-10-17 2019-05-08 Fresenius Medical Care Holdings, Inc. Method of determining a phosphorus binder dosage for a dialysis patient
WO2010093285A1 (en) * 2009-02-12 2010-08-19 Aduro Material Ab Composition comprising biodegradable carrier for controlled drug delivery
CN101580260B (zh) 2009-05-31 2011-04-27 河南大学 一种微乳液法制备无定形碳酸钙的方法
EP2598579B1 (de) 2010-07-30 2024-09-11 Schaefer Kalk GmbH & Co. KG Kugelförmige, amorphe calciumcarbonat-teilchen
CN103200938B (zh) 2010-08-30 2018-07-31 普马特里克斯营业公司 干燥粉末配方及用于治疗肺部疾病的方法
CN102085356B (zh) 2010-12-28 2013-02-27 北京同仁堂健康药业股份有限公司 一种用于增加骨密度的组合物及其制备方法
EP2702009A4 (en) 2011-04-28 2015-02-18 Calera Corp METHODS AND COMPOSITIONS USING CALCIUM CARBONATE AND STABILIZER
EP2790710B1 (en) 2011-12-13 2020-08-26 Amorphical Ltd. Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders
WO2014024191A1 (en) * 2012-08-07 2014-02-13 Amorphical Ltd. Method for producing stabilized amorphous calcium carbonate
JP2016507553A (ja) * 2013-02-11 2016-03-10 アモーフィカル リミテッド． 骨成長を促進する非晶質炭酸カルシウム
CN103663532B (zh) 2013-12-21 2015-10-28 中国科学院上海硅酸盐研究所 一种制备无定形碳酸钙纳米球的方法
RU2550865C1 (ru) * 2013-12-30 2015-05-20 Меграбян Казарос Аршалуйсович Способ получения карбоната кальция
EP3174409A4 (en) 2014-07-31 2018-01-17 Amorphical Ltd. Encapsulated amorphous calcium carbonate compositions
JP6873389B2 (ja) * 2016-01-18 2021-05-19 アモーフィカル リミテッド． 神経学的、筋肉、および不妊の疾患または症状の治療のための安定化無定形炭酸カルシウム

Also Published As

Publication number Publication date
BR112017026125A2 (pt) 2018-08-28
US12115184B2 (en) 2024-10-15
WO2016193983A1 (en) 2016-12-08
JP7039006B2 (ja) 2022-03-22
CL2017003066A1 (es) 2018-04-13
ES3056807T3 (en) 2026-02-24
EP3302505C0 (en) 2024-02-28
RU2739563C2 (ru) 2020-12-25
IL256065B1 (en) 2023-12-01
KR20180057603A (ko) 2018-05-30
US20200345763A1 (en) 2020-11-05
KR20180053632A (ko) 2018-05-23
BR112017026131B1 (pt) 2023-11-21
JP2018516929A (ja) 2018-06-28
WO2016193982A1 (en) 2016-12-08
EP3302506C0 (en) 2025-10-01
EP3302506A4 (en) 2018-12-19
EP3302505A1 (en) 2018-04-11
JP2022046688A (ja) 2022-03-23
HK1253702A1 (zh) 2019-06-28
RU2017145305A3 (es) 2019-08-14
EP3302505A4 (en) 2019-02-06
HK1253701A1 (zh) 2019-06-28
CN117137872A (zh) 2023-12-01
CA2988060C (en) 2023-09-05
JP2018516930A (ja) 2018-06-28
RU2748976C2 (ru) 2021-06-02
CN107921060A (zh) 2018-04-17
KR102833797B1 (ko) 2025-07-14
CA2988060A1 (en) 2016-12-08
IL256065A (en) 2018-01-31
EP3302506B1 (en) 2025-10-01
AU2016273059A1 (en) 2018-01-18
AU2016273058A1 (en) 2018-01-18
AU2016273058B2 (en) 2021-05-20
AU2021204073A1 (en) 2021-07-29
IL256065B2 (en) 2024-04-01
RU2017145291A3 (es) 2019-11-14
CA2988068C (en) 2024-01-09
JP7007716B2 (ja) 2022-01-25
BR112017026131A2 (pt) 2018-08-28
AU2021204073B2 (en) 2023-03-30
IL256064B1 (en) 2023-12-01
IL256064A (en) 2018-01-31
EP3302506A1 (en) 2018-04-11
US11033576B2 (en) 2021-06-15
JP7360738B2 (ja) 2023-10-13
US11052107B2 (en) 2021-07-06
US20180140631A1 (en) 2018-05-24
US20210308178A1 (en) 2021-10-07
EP3302505B1 (en) 2024-02-28
RU2017145291A (ru) 2019-07-09
CA2988068A1 (en) 2016-12-08
US20180153930A1 (en) 2018-06-07
CN107921061A (zh) 2018-04-17
US10758565B2 (en) 2020-09-01
IL256064B2 (en) 2024-04-01
RU2017145305A (ru) 2019-07-10
AU2016273059B2 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
CL2017003095A1 (es) Carbonato de calcio amorfo estabilizado con polifosfatos o bisfosfonatos
NI201600018A (es) Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
CL2016003246A1 (es) Compuestos de dihidroisoquinolinona sustituida
UY35821A (es) Compuesto heterocíclico
DOP2017000048A (es) Compuestos aminopirimidinilo como inhibidores de jak.
MX2016010296A (es) Compuestos farmaceutios.
CL2016002169A1 (es) Inhibidores de diacilglicerol aciltransferasa 2 para uso en el tratamiento de trastornos metabólicos y relacionados.
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
BR112017013448A2 (pt) composições líquidas de herbicidas contendo sulfonilureia
CL2018000007A1 (es) Compuestos inhibidores de la señalización de la vía de notch
CL2015002608A1 (es) Compuesto de amino-pirazol y usos medicinales relacionados.
AR106025A1 (es) Formas cristalinas de ácido siálico o una sal o solvato de este
MX374958B (es) Sal de cloruro de tat-nr2b9c.
CL2015002488A1 (es) Sal de abexinostato novedosa, forma cristalina relacionada, método de preparación de esta y las composiciones farmacéuticas que la contienen
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
UY36263A (es) Compuestos de tiazin-2-amina fusionados con ciclopropilo como inhibidores de beta-secretasa y métodos de uso
MX384392B (es) Moduladores heterocíclicos de la síntesis de lípidos para su uso contra el cáncer e infecciones virales.
ECSP17074919A (es) Piroglutamato de vortioxetina
MX2017002737A (es) Farmaceutico que contiene inhibidor de transportador de fosfato dependiente de sodio.
MX374241B (es) Formulación de triamida fosfórica o tiofosfórica altamente concentrada.
MX2020005564A (es) Sales de 4-amino-n-(1-((3-cloro-2-fluorofnil)amino)-6-metilisoquin olin-5-il)tieno[3,2-d]pirimidino-7-carboxamida, y formas cristalinas de las mismas.